Allogene Therapeutics Inc. (ALLO)’s Financial Results Comparing With Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN)

This is a contrast between Allogene Therapeutics Inc. (NASDAQ:ALLO) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) based on their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Allogene Therapeutics Inc. 28 0.00 N/A -2.05 0.00
Biohaven Pharmaceutical Holding Company Ltd. 50 0.00 N/A -5.29 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Allogene Therapeutics Inc. and Biohaven Pharmaceutical Holding Company Ltd.

Profitability

Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Allogene Therapeutics Inc. 0.00% 0% 0%
Biohaven Pharmaceutical Holding Company Ltd. 0.00% -201.4% -89.8%

Liquidity

The Current Ratio and Quick Ratio of Allogene Therapeutics Inc. are 17.5 and 17.5 respectively. Its competitor Biohaven Pharmaceutical Holding Company Ltd.’s Current Ratio is 9.6 and its Quick Ratio is 9.6. Allogene Therapeutics Inc. can pay off short and long-term obligations better than Biohaven Pharmaceutical Holding Company Ltd.

Analyst Ratings

The table shown features the ratings and recommendations for Allogene Therapeutics Inc. and Biohaven Pharmaceutical Holding Company Ltd.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Allogene Therapeutics Inc. 0 0 2 3.00
Biohaven Pharmaceutical Holding Company Ltd. 0 1 5 2.83

The upside potential is 31.86% for Allogene Therapeutics Inc. with consensus price target of $43.5. On the other hand, Biohaven Pharmaceutical Holding Company Ltd.’s potential upside is 66.71% and its consensus price target is $78.17. The data from earlier shows that analysts view suggest that Biohaven Pharmaceutical Holding Company Ltd. seems more appealing than Allogene Therapeutics Inc.

Institutional & Insider Ownership

Institutional investors held 51.4% of Allogene Therapeutics Inc. shares and 80.7% of Biohaven Pharmaceutical Holding Company Ltd. shares. Allogene Therapeutics Inc.’s share held by insiders are 3.3%. Insiders Competitively, held 11.2% of Biohaven Pharmaceutical Holding Company Ltd. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Allogene Therapeutics Inc. 8.32% 9.39% 5.19% 2.31% 0% 15.11%
Biohaven Pharmaceutical Holding Company Ltd. -3.02% -0.51% -25.7% 12.38% 29.17% 16.39%

For the past year Allogene Therapeutics Inc.’s stock price has smaller growth than Biohaven Pharmaceutical Holding Company Ltd.

Summary

Allogene Therapeutics Inc. beats Biohaven Pharmaceutical Holding Company Ltd. on 5 of the 8 factors.

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is headquartered in South San Francisco, California.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. The company also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.